New ion channel drug targets to emerge in pharmaceutical discovery

The identification and structural determination of channel proteins, and their validation as therapeutic targets using high throughput cell based and multiplexed screening technologies, have furnished an increase role for ion channel targets in the drug discovery and development pipelines in the pharmaceutical and biotechnology industries.

The structure and function of new targets, including TRP, CLIC, and CRAC channels, allosteric modulation, applications in high throughput screening, as well as safety data from QT Prolongation and hERG studies, are the focus of an annual conference and exhibition to be held in Philadelphia, PA, announces Strategic Research Institute.

The meeting is the 5th in the successful series, and has been expanded to comprehensively cover newly characterized ion channels and their mechanistic implications for drug discovery and challenges in clinical development.

Leading pharmaceutical industry and academic scientists from Pfizer, Johnson & Johnson Pharmaceutical Research & Development, Scion Pharmaceuticals, Merck, Abbott, Wyeth, Molecular Devices, Schering, Chantest, Sophion, and the NCI/NIH are among the distinguished faculty confirmed to address the plenary via keynote and technical presentations and panel discussions.

Topics to be covered include:

• New and Validated Targets
• Ion Channel Structure and Function
• Allosteric Modulation
• Ion-Channelopathies and Disease States
• High Throughput Screening
• EP and Patchclamp Technologies
• Discovery Implications for CNS, Cardiovascular, Oncology, and Inflammation
• Drug Development & Safety Evaluation
• QT Prolongation
• hERG
• Panel Discussion: Challenges in the Clinical Development of Ion Channel Drugs

To request announcement, or for a list of past registrants, please send full contact information to Steve J. Kuperberg at [email protected] or call (212) 967-0095 x261.

For agenda and registration, visit http://www.srinstitute.com/cs338